Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 194,515 | 154,178 | 120,700 | 110,565 | 116,633 |
| Cost of Goods | 9,939 | 8,107 | 6,563 | 3,653 | 2,639 |
| Gross Profit | 184,576 | 146,071 | 114,137 | 106,912 | 113,994 |
| Operating Expenses | 291,471 | 285,740 | 259,899 | 241,843 | 219,005 |
| Operating Income | -105,956 | -139,562 | -145,199 | -134,278 | -104,372 |
| Interest Expense | 52,815 | 50,314 | 48,149 | 37,637 | 42,141 |
| Other Income | -7,784 | -4,879 | 6,866 | -9,743 | -23,095 |
| Pre-tax Income | -166,555 | -194,755 | -186,482 | -181,658 | -169,608 |
| Income Tax | N/A | -120 | -1,545 | 2,100 | N/A |
| Net Income Continuous | -166,555 | -194,635 | -184,937 | -183,758 | -169,608 |
| Minority Interests | -2,512 | -1,772 | -2,194 | -1,855 | -2,186 |
| Net Income | $-164,043 | $-192,863 | $-182,743 | $-181,903 | $-167,422 |
| EPS Basic Total Ops | -0.84 | -1.00 | -0.95 | -0.95 | -0.88 |
| EPS Basic Continuous Ops | -0.86 | -1.01 | -0.96 | -0.96 | -0.89 |
| EPS Diluted Total Ops | -0.84 | -1.00 | -0.95 | -0.95 | -0.88 |
| EPS Diluted Continuous Ops | -0.86 | -1.01 | -0.96 | -0.96 | -0.89 |
| EPS Diluted Before Non-Recurring Items | -0.84 | -1.00 | -0.95 | -0.95 | -0.88 |
| EBITDA(a) | $-102,951 | $-132,160 | $-143,801 | $-134,582 | $-101,467 |